Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose escalation trial of OPC-67683 in pulmonary multidrug-resistant tuberculosis
2009-014944-13Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delamanid in pulmonary tuberculosis (TB), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety and tolerability of OPC-67683. Started Sep 2009; status: completed.
02
Drugs
delamanid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2009-014944-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014944-13.